We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Sino Biological and Ainnocence Partner To Offer Next-Generation Antibody Development CRO Services
Product News

Sino Biological and Ainnocence Partner To Offer Next-Generation Antibody Development CRO Services

Sino Biological and Ainnocence Partner To Offer Next-Generation Antibody Development CRO Services
Product News

Sino Biological and Ainnocence Partner To Offer Next-Generation Antibody Development CRO Services


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Sino Biological and Ainnocence Partner To Offer Next-Generation Antibody Development CRO Services"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Sino Biological, Inc. (“Sino Biological” or the “Company”), a biotechnology company listed on the Shenzhen stock exchange subsidiary ChiNext (SZSE: 301047), which provides biological research reagents and related technical contract research services, is pleased to announce a CRO services partnership with Ainnocence, Inc. of San Jose, California. Under the terms of this partnership, Sino Biological will add Ainnocence’s cutting-edge artificial intelligence-based prediction technology to its current antibody development CRO services offering. The AI-based platform enables fast, efficient, and accurate prediction of antibody-antigen interaction, including binding affinity assessment. This empowers Ainnocence, using computer-based algorithms, to accurately design antibodies to be developed and manufactured by Sino Biological for clients worldwide.  Financial terms were not disclosed.


Dr. Rob Burgess, Sino Biological’s Chief Business Officer, stated “The addition of Ainnocence’s AI-based antibody-antigen binding prediction technology will enable Sino Biological to further enhance its antibody development CRO services offering, thus saving customers precious development time and ensuring antibody-antigen binding affinities that meet their strict demands. We look forward to working with the Ainnocence team to offer next-generation antibody design and development services.”


“I’m confident that our partnership with Sino Biological will catalyze Ainnocence’s Biologics AI design applications in the biotech industry, and ultimately accelerate clinical translation of cutting-edge medical technologies.” stated Dr. Lurong Pan, Ainnocence CEO.

  

Advertisement